2022 Neuro-oncology Reading List, Learning Objectives, and CME

Reading List

Please click below to access the 2022 Neuro-oncology reading list.

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty  journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

• Correctly apply WHO 2021 classification criteria for diagnosis of diffuse gliomas and recommend appropriate therapy for newly diagnosed glioma patients based on these updated criteria
• Appropriately apply the results of clinical trials in glioma treatment (applies to both CATNON/CODEL)
• Understand the diagnosis and management of neurologic complications in brain tumors in adults and children
• Understand the role and clinical implications of novel targeted agents in the treatment of ependymoma, primary CNS lymphoma, and plexiform neurofibroma

Core Competencies

• Medical Knowledge

Continuing Medical Education (CME) Instructions

To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within 24 hours of passing the quiz.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Academy of Neurology Institute designates this enduring material for a maximum of 15 AMA PRA Category 1^TM credit(s). Physicians should claim only their credit commensurate with the extent of the participation in the activity.

ABPN Self-Assessment Designation Statement

The American Board of Psychiatry & Neurology (ABPN) has reviewed the UCNS Continuous Certification (C-cert) self-assessment activity and has approved the program as a part of a comprehensive self-assessment (SA) program, which is mandates by the American Board of Medical Specialties as a necessary component of maintenance of certification. The number of ABPN SA credits granted will equal the number of CME hours claimed for the activity. 

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy. 

2022 C-cert Activity Planner Disclosures
All relevant financial relationships have been mitigated.

Neuro-oncology Certification Examination Committee Contributors

David M. Cachia, MD, Chair, UMass Memorial Medical Center
Disclosures: Receives personal compensation for serving as Bayer USA advisory board member. 

Christian Grommes, MD, Vice Chair, Memorial Sloan Kettering Cancer Center
Disclosures: Receives personal compensation for serving on advisory board for BTG, Kite, and Ono. Received grant funding for research from Bayer, BMS, BTG, and Pharmacyclics.

Joy E. Burke, MD, Beth Israel Lahey Health, Lahey Clinic
Disclosures: Nothing to disclose. 

Yasmin Khakoo, MD, Memorial Sloan Kettering Cancer Center
Disclosures: Receives personal compensation for serving as Editor-in-Chief for Pediatric Neurology (Elsevier). Receives grant funding for research from Nevus Outreach, Inc. (nonprofit, tax-exempt organization).

Heather E. Leeper, MD, National Institute of Health – National Cancer Institute
Disclosures: Nothing to disclose.

Douglas E. Ney, MD, University of Colorado – Anschutz Medical Campus
Disclosures: Receives compensation to serve on DNAtrix Therapeutics - Data Safety Monitoring Board. Receives research support from Orbus Therapeutics – clinical trial sponsor and from Denovo Biopharm – clinical trial sponsor.

Katherine B. Peters, MD, PhD, Duke University Medical Center
Disclosures: Receives personal compensation for serving on Advisory Boards of Agios and Sapience. Received research support from Agios, Abbvie, and Biomimetix. Served on Society of Neuro-oncology Review Course for Neuro-oncology.

Roy E. Strowd, III, MD, MEd, Wake Forest Baptist Health
Disclosures: Receives consulting fees from Novocure and Monteris Medical; receives royalties from Lecturio for online lectures in neurology; receives research support from JAZZ Pharmaceuticals and Alpha Omega Alpha. Research work funded by grants from National Institutes of Health and American Board of Psychiatry and Neurology.

Joon Uhm, MD, Mayo Clinic – Rochester 
Disclosures: Receives speaker fees from Zai Labs for speaking engagements at CME meetings, with topics focused on current approaches to brain tumor therapies as well as tumor treatment field device.

Andrea Wasilewski, MD, Givens Brain Tumor Center
Disclosures: Nothing to disclose.

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326